Scholarlink

Introduction <p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common cancer worldwide. For patients with unresectable, localized, intermediate-stage HCC, the standard treatment is transarterial chemoembolization (TACE).</p> Methods <p>Given the recent advances in systemic treatments for HCC with immunotherapy and targeted therapies, several studies have explored the potential benefits of combining TACE with systemic therapy, owing to the possible synergistic effects. This review analyzes recent clinical studies of patients with unresectable HCC who received TACE in combination with different classes of systemic therapies.</p> Conclusion <p>Collectively, these studies suggest that combining TACE with systemic therapy may enhance treatment response and improve survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma

  • 期刊论文

  • 发表日期：

    2025年9月27日

查看全文
  • Arif Akyildiz,
  • Betul Gok Yavuz,
  • Rashad Ismayilov,
  • Muge Buyukaksoy,
  • Sena Sozen,
  • Joe Ramzi Eid,
  • Rony Avritscher,
  • Lee Sunyoung,
  • Suayib Yalcin,
  • Ahmed O. Kaseb

摘要

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common cancer worldwide. For patients with unresectable, localized, intermediate-stage HCC, the standard treatment is transarterial chemoembolization (TACE).

Methods

Given the recent advances in systemic treatments for HCC with immunotherapy and targeted therapies, several studies have explored the potential benefits of combining TACE with systemic therapy, owing to the possible synergistic effects. This review analyzes recent clinical studies of patients with unresectable HCC who received TACE in combination with different classes of systemic therapies.

Conclusion

Collectively, these studies suggest that combining TACE with systemic therapy may enhance treatment response and improve survival outcomes.